iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite
NVIDIA platform streamlines adoption,
accelerates deployment of iCAD’s solutions in virtualized data centers
NASHUA, N.H. – March 2, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced that it is among the first to validate its AI solutions with
theNVIDIA® AI
Enterprise software suite. The Company’s breast health technologies, includingProFound AI®,PowerLook® Density
Assessment andProFound AI® Risk, can now be deployed with the
NVIDIA AI Enterprise software suite, which enables thousands of healthcare
organizations worldwide to virtualize AI workloads within hospital data centers
using VMware vSphere and industry-standard servers.
“With iCAD’s deep learning algorithms now available to deploy on
NVIDIA AI Enterprise and virtualized infrastructure, more facilities can
accelerate the rapid deployment, management, and scaling of iCAD’s leading-edge
solutions,” said Stacey Stevens, President and CEO of iCAD, Inc. “For hospitals
that are currently using or migrating towards AI – particularly large hospital
networks and academic institutions – this will make it a more seamless
experience to adopt our technologies and fully unlock their potential, using
users’ preferred data center virtualization infrastructure.”
iCAD’s breast health solutions help clinicians to accurately and
efficiently identify cancers, categorize breast density, and assess short-term
personalized breast cancer risk. With NVIDIA AI Enterprise, the AI rollout
process is simplified, as the software suite enables IT administrators to run
and manage multiple AI applications on the same hardware, in their preferred,
virtualized infrastructure.
“As one of the first healthcare companies to fast-track
integration with the NVIDIA software suite, iCAD is on the leading edge of
hospital enterprise-class deployments,” said Brad Genereaux, Medical Imaging
Alliance Manager at NVIDIA. “NVIDIA AI Enterprise streamlines the integration
of AI into existing infrastructure by enabling IT administrators to manage all
applications, including iCAD’s suite of breast health solutions, in one central
environment — which maximizes the facility’s investments and makes adopting new
technologies more affordable and accessible.”
iCAD’s full suite of breast health solutions includes ProFound AI,
which is available for 2D and 3D mammography, PowerLook Breast Density
Assessment, which aids in accurate and consistent density-based stratification
and reporting, and ProFound AI Risk, the world’s first and only clinical
decision support tool that provides an accurate short-term, breast cancer risk
estimation that is truly personalized for each woman based only on a screening
mammogram.
“With many facilities still reeling from the impact of the
pandemic, AI is becoming an increasingly critical tool for radiologists to
overcome clinical, economic, and volume-based challenges,” added Stevens. “And
with our recent focus on expanding enterprise sales opportunities, which
typically involve engaging with a unique triad of economic, clinical and IT
decision-makers at facilities, iCAD’s highly trained, clinically proven
technologies are now more easily accessible to hospitals running AI on
virtualized infrastructure with NVIDIA GPUs.”
The first AI cancer detection software for digital breast
tomosynthesis to be cleared by the FDA, ProFound AI is clinically proven to
reduce radiologists’ reading time by 52.7 percent, improve radiologists’
sensitivity by eight percent and reduce unnecessary patient recall rates by 7.2
percent.[i]
Additionally, ProFound AI was found to cut reading time by up to 57.4 percent
for radiologists reading cases of women with dense breasts.[ii]
ProFound AI Risk offers the ability to calculate a short-term risk
estimation for 2D and 3D mammography, with greater accuracy compared to both
the previous version of the risk software based on 2D mammography and
traditionally used risk models. The latest version of the software was
specifically designed to factor in racial and ethnic backgrounds, as well as
clinically relevant global screening guidelines and more than 15 country
incidence and mortality reference tables, for alignment with that country’s general
population.
PowerLook Density Assessment software enables clinicians to
automate breast density assessment accurately and reliably, removing the
challenges of subjectivity. Built with the latest in deep-learning and
compatible with multiple vendors, this advanced solution identifies the
patient’s anatomy, segments the breast, then measures adipose and
fibroglandular tissue and its dispersion to determine the density category in
alignment with BI-RADS® 5th Edition lexicon.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD® is a global medical technology
leader providing innovative cancer detection and therapy solutions. For more
information, visit www.icadmed.com.
Forward-Looking Statements
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements about the expected benefits of ProFound AI®, the
benefits of the Company’s products, and future prospects for the Company’s
technology platforms and products. Such forward-looking statements involve a
number of known and unknown risks, uncertainties and other factors which may
cause the actual results, performance, or achievements of the Company to be
materially different from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such factors include,
but are not limited, to the Company’s ability to achieve business and strategic
objectives, the willingness of patients to undergo mammography screening in
light of risks of potential exposure to Covid-19, whether mammography screening
will be treated as an essential procedure, whether ProFound AI will improve
reading efficiency, improve specificity and sensitivity, reduce false positives
and otherwise prove to be more beneficial for patients and clinicians, the
impact of supply and manufacturing constraints or difficulties on our ability
to fulfill our orders, uncertainty of future sales levels, to defend itself in
litigation matters, protection of patents and other proprietary rights, product
market acceptance, possible technological obsolescence of products, increased
competition, government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt obligations,
competitive factors, the effects of a decline in the economy or markets served
by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,”
“expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and
similar expressions identify forward-looking statements. Readers are cautioned
not to place undue reliance on those forward-looking statements, which speak
only as of the date the statement was made. The Company is under no obligation
to provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD, please see
the disclosure contained in our public filings with the Securities and Exchange
Commission, available on the Investors section of our website at
http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contact:
Media
Inquiries:
Jessica
Burns, iCAD
+1-201-423-4492
iCAD
Investor Relations:
[i] Conant,
E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of
Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial
Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096.
[ii] Hoffmeister,
J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader
Study Results. [White paper]. Accessed via
https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf